Polaris Group

Equities

6550

KYG7171A1085

Biotechnology & Medical Research

End-of-day quote Taiwan S.E. Other stock markets 18:00:00 2024-05-21 EDT			5-day change	1st Jan Change
69.8 ^TWD	-0.85%		-2.10%	-7.67%

05-14	Polaris Group Announces Change of the Member of Compensation Committee	CI
2023	Polaris Group Announces the Appointment of K Evin Wu	CI

Soliton Systems, K.K. cancelled the acquisition of OREGA Inc. from Polaris Group Ltd., Osamu Miyoshi, Eiichiro Shiota and 27 other individuals.

June 21, 2017

Soliton Systems, K.K. (JASDAQ:3040) entered into an agreement to acquire OREGA Inc. from Polaris Group Ltd., Osamu Miyoshi, Eiichiro Shiota and 27 other individuals on June 22, 2016. As per the agreement Soliton will acquire Orega through stock swap under which 93 shares of Soliton will be swapped for 1 share of Orega. The transaction is expected to complete on July 28, 2016.

Soliton Systems, K.K. (JASDAQ:3040) cancelled the acquisition of OREGA Inc. from Polaris Group Ltd., Osamu Miyoshi, Eiichiro Shiota and 27 other individuals on June 22, 2017.

Latest news about Polaris Group

Polaris Group Announces Change of the Member of Compensation Committee	05-14	CI
Polaris Group Announces the Appointment of K Evin Wu	12-21	CI
Polaris Group Announces Chief Executive Officer Changes, Effective December 21, 2023	12-21	CI
Polaris Group agreed to acquire additional unknown stake in Genovior Biotech Corporation for TWD 2 billion.	12-20	CI
Polaris Group Announces First Patient Successfully Dosed with ADI-PEG 20 in Phase II Clinical Trial for NASH at Chang Gung Memorial Hospital, Linkou, Taiwan	11-29	CI
Polaris Group Initiates Rolling Submission of Biologic License Application for ADI-PEG 20 with U.S. FDA to Treat Malignant Pleural Mesothelioma	11-16	CI
Polaris Group Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	11-10	CI
Polaris Group announced a financing transaction	23-10-05	CI
Polaris Group Appoints K.C. Tsai as Compensation Committee Member	23-09-26	CI
TDW HK Limited announced that it has received $17 million in funding from Polaris Group	23-09-25	CI
Polaris Group Announces Resignation of TAI, JANG-HUEI as Audit Committee and Remuneration Committee Member	23-08-29	CI
Polaris Group Announces of Resignation of TAI, JANG-HUEI as Independent Director	23-08-29	CI
Polaris Group Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-24	CI
Polaris Group Announces Dosing of First Patient in Phase 2 Trial of ADI-PEG 20 with Radiation and TMZ in Patients with GBM	23-08-04	CI
Polaris Group Partners with MatrixCare to Improve MDS Assessment Accuracy for Long-Term Care Communities	23-07-27	CI
Polaris Group Announces MFDS Approves Phase Phase 2 Clinical Protocol Treating GBM with ADI-PEG 20	23-06-27	CI
Polaris Group Appoints Chien-Hsing Chang as Chief Strategy Officer Effective June 20, 2023	23-06-12	CI
Polaris Group Announces Executive Changes Effective June 15, 2023	23-06-12	CI
Polaris Group Announces that TFDA Approves Phase3 Clinical Protocol Treatment HCC with ADI-PEG 20	23-05-30	CI
Polaris Group and Vietnam National Cancer Center Announce the Signing of MOU for Future Collaboration	23-05-29	CI
Polaris Group Submits ADI-PEG 20 to TFDA for INR as Treatment for Hepatocellular Carcinoma	23-05-04	CI
DesigneRx Pharmaceuticals, Inc. announced that it expects to receive $15 million in funding from Polaris Group	23-04-23	CI
Polaris Group Announces the Submission of Polyaris 2020-001 Phase 2 Trial of ADI-PEG 20 to MFDS	23-04-13	CI
Polaris Group Receives Pre-BLA Meeting Notice from US FDA for ADI-PEG 20	23-02-03	CI
Polaris Group Receives IND Approval from US FDA for the Investigational New Drug of ADI-PEG 20 to Treat Soft Tissue Sarcoma	23-01-21	CI

Chart Polaris Group

Duration

Period

More charts

Company Profile

Polaris Group is a Cayman Islands-based biopharmaceutical company, which is engaged in advanced therapies, primarily focusing on metabolic related diseases. The Companyâs drug candidate, Pegargiminase (ADI-PEG 20), is advancing through the biologics license applications (BLA) - enabling stage and clinical development. Pegargiminase (ADI PEG 20), is a biologic in late-stage clinical development for a wide range of cancers, including hepatocellular carcinoma, mesothelioma, pancreatic cancer, non-small cell lung cancer, melanoma, acute myeloid leukemia and others. Pegargiminase is designed to disrupt cancer cell metabolism, providing a novel approach to treating a range of cancers heavily influenced by metabolic pathways. The Companyâs product pipeline also includes peptide drugs, such as the Semaglutide-related products.

Sector

Biotechnology & Medical Research

Calendar

2024-08-08 - Q2 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Annual profits - Rate of surprise

Company calendar

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
POLARIS GROUP	-7.67%	1.62B
MODERNA, INC.	+64.23%	55.07B
IQVIA HOLDINGS INC.	-2.31%	41.79B
LONZA GROUP AG	+44.36%	40.22B
CELLTRION, INC.	-8.29%	28.17B
ICON PUBLIC LIMITED COMPANY	+11.97%	26.28B
ALNYLAM PHARMACEUTICALS, INC.	-21.16%	18.93B
BIO-TECHNE CORPORATION	+7.54%	13.03B
MEDPACE HOLDINGS, INC.	+27.17%	12.26B
UNITED THERAPEUTICS CORPORATION	+25.72%	12.21B

Other Biotechnology & Medical Research